Abstract

Covid-19 is caused by a new virus and no effective therapy is available. The following article presents the case of a 47-year-old woman with SARS-CoV-2 infection. The infection was initially mild but because of exacerbation of the symptoms: cough, fever, headache, extreme weakness she was admitted to the hospital. The chest X-ray revealed pneumonia due to Covid-19, that is why CT was not done. Due to persistent symptoms of infection, therapy containing chloroquine and azithromycin was introduced, obtaining a very quick improvement in the condition of the infected patient. Because of ambiguous opinions of the efficacy of these two drugs in the therapy of SARS-CoV-2 infection, the authors wonder whether the improvement was either a result of the treatment with chloroquine and azithromycin or because of the natural Covid-19 course. The following part of the article briefly reviews research and world reports as well as problems connected with chloroquine and hydroxychloroquine therapy in patients with Covid-19. The current positions of the World Health Organization (WHO) and the Food and Drug Administration (FDA) in terms of the topic were also presented. It was also pointed out the way unprecedented before the therapy has been introduced based on several and variable report about the efficacy and safety of these drugs.

References

• 1. Alexander P.E., Borg Debono V., Mammen M.J., Iorio A., AryalK., Deng D., Brocard E., Alhazzani W.: COVID-19 coronavirus researchhas overall low methodological quality thus far: Case inpoint for chloroquine/hydroxychloroquine. J. Clin. Epidemiol.,2020; 123: 120–126 2 Arshad S., Kilgore P., Chaudhry Z.S., Jacobsen G., Wang D.D.,Huitsing K., Brar I., Alangaden G.J., Ramesh M.S., McKinnon J.E.,O’Neill W., Zervos M., Henry Ford COVID-19 Task Force: Treatmentwith hydroxychloroquine, azithromycin, and combinationin patients hospitalized with COVID-19. Int. J. Infect. Dis., 2020;97: 396–403
  Google Scholar
• 2. infection. CMAJ, 2020; 192: E450–E453
  Google Scholar
• 3. Beigel J.H., Tomashek K.M., Dodd L.E., Mehta A.K., ZingmanB.S., Kalil A.C., Hohmann E., Chu H.Y., Luetkemeyer A., Kline S., deCastilla D.L., Finberg R.W., Dierberg K., Tapson V., Hsieh L., et al.:Remdesivir for the Treatment of Covid-19 — Preliminary Report.N. Engl. J. Med., 2020, https://www.nejm.org/doi/full/10.1056/NEJMoa2007764 (17.07.2020)
  Google Scholar
• 4. Borba M.G., Val F.F., Sampaio V.S., Araújo Alexandre M.A., CardosoMelo G., Brito M., Gomes Mourão M.P., Brito-Sousa J.D., Baiada-Silva D., Guerra M.V., Abrahão Hajjar L., Costa Pinto R., SilvaBalieiro A.A., Fonseca Pacheco A.G., Santos J.D., et al: Effect of highvs low doses of chloroquine diphosphate as adjunctive therapyfor patients hospitalized with severe acute respiratory syndromecoronavirus 2 (SARS-CoV-2) infection. A randomized clinical trial.JAMA Netw. Open, 2020; 3: e208857
  Google Scholar
• 5. Cavalcanti A.B., Zampieri F.G., Rosa R.G., Azevedo L.C., Veiga,V.C., Avezum A., Damiani L.P., Marcadenti A., Kawano-DouradoL., Lisboa T., Junqueira D.L., de Barros e Silva P.G., Tramujas L.,Abreu-Silva E.O., Laranjeira L.N., et al.: Hydroxychloroquine withor without azithromycin in mild-to-moderate Covid-19. N. Engl.J. Med., 2020, https://www.nejm.org/doi/10.1056/NEJMoa2019014(29.07.2020)
  Google Scholar
• 6. Charakterystyka produktu leczniczego Arechin, 250 mg, tabletki.http://www.urpl.gov.pl/sites/default/files/Arechin%20Charakterystyka%20Produktu%20Leczniczego.pdf
  Google Scholar
• 7. Chatre C., Roubille F., Vernhet H., Jorgensen C., Pers Y.M.: Cardiaccomplications attributed to chloroquine and hydroxychloroquine:A systematic review of the literature. Drug Saf., 2018;41: 919–931
  Google Scholar
• 8. Colson P., Rolain J.M., Lagier J.C., Brouqui P., Raoult D.: Chloroquineand hydroxychloroquine as available weapons to fightCOVID-19. Int. J. Antimicrob. Agents, 2020; 55: 105932
  Google Scholar
• 9. Colson P., Rolain J.M., Raoult D.: Chloroquine for the 2019 novelcoronavirus SARS-CoV-2. Int. J. Antimicrob. Agents, 2020; 55:105923
  Google Scholar
• 10. Cortegiani A., Ingoglia G., Ippolito M., Giarratano A., Einav S.:A systematic review on the efficacy and safety of chloroquine forthe treatment of COVID-19. J. Crit. Care, 2020; 57: 279–283
  Google Scholar
• 11. De Lamballerie X., Boisson V., Reynier J.C., Enault S., CharrelR.N., Flahault A., Roques P., Le Grand R.: On chikungunya acuteinfection and chloroquine treatment. Vector Borne Zoonotic Dis.,2008; 8: 837–839
  Google Scholar
• 12. Delvecchio R., Higa L.M., Pezzuto P., Valadão A.L., Garcez P.P.,Monteiro F.L., Loiola E.C., Dias A.A., Silva F.J., Aliota M.T., Caine E.A.,Osario J.E., Bellio M., O’Connor D.H., Rehen S., Santana R., de AguiarR., et al.: Chloroquine, an endocytosis blocking agent, inhibitsZika virus infection in different cell models. Viruses, 2016; 8: 322
  Google Scholar
• 13. de Wilde A.H., Jochmans D., Posthuma C.C., Zevenhoven-DobbeJ.C., van Nieuwkoop S., Bestebroer T.M., van den Hoogen B.G., NeytsJ., Snijder E.J.: Screening of an FDA-approved compound libraryidentifies four small-molecule inhibitors of Middle East RespiratorySyndrome coronavirus replication in cell culture. Antimicrob.Agents Chemother., 2014; 58: 4875–4884
  Google Scholar
• 14. dos Santos W.G.: Natural history of COVID-19 and currentknowledge on treatment therapeutic options. Biomed. Pharmacother.,2020; 129: 1104934
  Google Scholar
• 15. Dowall S.D., Bosworth A., Watson R., Bewley K., Taylor I.,Rayner E., Hunter L., Pearson G., Easterbrook L., Pitman J., HewsonR., Carroll M.W.: Chloroquine inhibited Ebola virus replicationin vitro but failed to protect against infection and disease inthe in vivo guinea pig model. J. Gen. Virol., 2015; 96: 3484–3492
  Google Scholar
• 16. FDA cautions against use of hydroxychloroquine or chloroquinefor COVID-19 outside of the hospital setting or a clinicaltrial due to risk of heart rhythm problems. Drug Safety Communication;https://www.fda.gov/media/137250/download(24.04.2020)
  Google Scholar
• 17. FDA issues emergency use authorization for chloroquine,hydroxychloroquine for COVID-19 patients. www.trussvilletribune.com/2020/03/30/breaking-fda-issues-emergency-useauthorization-for-chloroquine-hydroxychloroquine-for-covid-19-patients/ (19.07.2020)
  Google Scholar
• 18. Gao J., Tian Z., Yang X.: Breakthrough: chloroquine phosphatehas shown apparent efficacy in treatment of COVID-19associated pneumonia in clinical studies. Biosci. Trends, 2020;14: 72–73 19 Gautret P., Lagier J.C., Parola P., Hoang V.T., Meddeb L., MailheM., Doudier B., Courjon J., Giordanengo V., Vieira V.E., DupontH.T., Honore S., Colson P., Chabriere E., La Scola B., et al.: Hydroxychloroquineand azithromycin as a treatment of COVID-19:results of an open label non-randomized clinical trial. Int. J. Antimicrob.Agents, 2020; 56: 105949
  Google Scholar
• 19. (15.07.2020)
  Google Scholar
• 20. Geleris J., Sun Y., Platt J., Zucker J., Baldwin M., Hripcsak G.,Labella A., Manson D.K., Kubin C., Barr R.G., Sobieszczyk M.E.,Schluger N.W.: Observational study of hydroxychloroquine inhospitalized patients with Covid-19. N. Engl. J. Med., 2020; 382:2411–2418
  Google Scholar
• 21. Inglot A.D.: Comparison of the antiviral activity in vitroof some non-steroidal anti-inflammatory drugs. J. Gen. Virol.,1969; 4: 203–214
  Google Scholar
• 22. Juurlink D.N.: Safety considerations with chloroquine, hydroxychloroquineand azithromycin in the management of SARSCoV-
  Google Scholar
• 23. Keyaerts E., Vijgen L., Maes P., Neyts J., Van Ranst M.: Invitro inhibition of severe acute respiratory syndrome coronavirusby chloroquine. Biochem. Biophys. Res. Commun., 2004;323: 264–268
  Google Scholar
• 24. Mehra M.R., Desai S.S., Ruschitzka F., Patel A.N.: Hydroxychloroquineor chloroquine with or without a macrolide fortreatment of COVID-19: a multinational registry analysis. Lancet,2020, doi.org/10.1016/S0140-6736(20)31180-6 (22.05.2020)
  Google Scholar
• 25. Mehra M.R., Ruschitzka F., Patel A.N.: Retraction. Hydroxychloroquineor chloroquine with or without a macrolide fortreatment of COVID-19: a multinational registry analysis Lancet,2020; 395: 1820
  Google Scholar
• 26. Million M., Lagier J.C., Gautret P., Colson P., Fournier P.E.,Amrane S., Hocquart M., Mailhe M., Esteves-Vieira V., DoudierB., Aubry C., Correard F., Giraud-Gatineau A., Roussel Y., BerengerC., et al.: Early treatment of 1061 COVID-19 patients withhydroxychloroquine and azithromycin: A retrospective analysisof 1061 cases in Marseille, France. Travel Med. Infect. Dis.,2020; 35: 101738
  Google Scholar
• 27. Q&A: Hydroxychloroquine and COVID-19; https://www.who.int/news-room/q-a-detail/q-a-hydroxychloroquine-andcovid-
  Google Scholar
• 28. Rainsford K.D., Parke A.L., Clifford-Rashotte M., Kean W.F.:Therapy and pharmacological properties of hydroxychloroquineand chloroquine in treatment of systemic lupus erythematosus,rheumatoid arthritis and related diseases. Inflammopharmacology,2015; 23: 231–269
  Google Scholar
• 29. Roden D.M., Harrington R.A., Poppas A., Russo A.M.: Considerationsfor drug interactions on QTc in exploratory COVID-19treatment. Circulation, 2020; 141: e906–e907
  Google Scholar
• 30. Rosenberg E.S., Dufort E.M., Udo T., Wilberschied L.A., KumarJ., Tesoriero J., Weinberg P., Kirkwood J., Muse A., DeHovitz J., BlogD.B., Hutton B., Holtgrave D.R., Zucker H.A.: Association of treatmentwith hydroxychloroquine or azithromycin with in-hospitalmortality in patients with COVID-19 in New York State. JAMA,2020; 323: 2493–2502
  Google Scholar
• 31. Schrezenmeier E., Dörner T.: Mechanisms of action of hydroxychloroquineand chloroquine: implications for rheumatology. Nat.Rev. Rheumatol., 2020; 16: 155–166
  Google Scholar
• 32. Tsai W.P., Nara P.L., Kung H.F., Oroszlan S.: Inhibition of humanimmunodeficiency virus infectivity by chloroquine. AIDS Res.Hum. Retroviruses, 1990; 6: 481–489
  Google Scholar
• 33. Vigerust D.J., McCullers J.A.: Chloroquine is effective against influenza A virus in vitro but not in vivo. Influenza Other Respir.Viruses, 2007; 1: 189–192
  Google Scholar
• 34. Vincent M.J., Bergeron E., Benjannet S., Erickson B.R., RollinP.E., Ksiazek T.G., Seidah N.G., Nichol S.T: Chloroquine is a potentinhibitor of SARS coronavirus infection and spread. Virol J.,2005; 2: 69
  Google Scholar
• 35. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z.,Zhong W., Xiao G.: Remdesivir and chloroquine effectively inhibitthe recently emerged novel coronavirus (2019-nCoV) in vitro. CellRes., 2020; 30: 269–271
  Google Scholar
• 36. Wang Y., Zhang D., Du G., Du R., Zhao J., Jin Y., Fu S., Gao L.,Cheng Z., Lu Q., Hu Y., Wang K., Lu Y., Li H., Wang S., et al.: Remdesivirin adults with severe COVID-19: a randomised, double-blind,placebo-controlled, multicentre trial. Lancet, 2020; 395: 1569–1578
  Google Scholar
• 37. WHO discontinues hydroxychloroquine and lopinavir/ritonavirtreatment arms for COVID-19. www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-andlopinavir-ritonavir-treatment-arms-for-covid-19 (19.07.2020)
  Google Scholar

Full text